Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 231

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review

Vansteenkiste, Johan, Fischer, Barbara M, Dooms, Christophe, Mortensen, Jann · 2004 · The Lancet Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(04)01564-5

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 48

  1. Vansteenkiste, 2001, The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology, Eur Respir J, 17, 802, 10.1183/09031936.01.17408020 · DOI
  2. Woodard, 1975, Expression of tissue isotope distribution, J Nucl Med, 16, 958
  3. Fischer, 2001, Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review, Lancet Oncol, 2, 659, 10.1016/S1470-2045(01)00555-1 · DOI · Paper page
  4. Gould, 2001, Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis, JAMA, 285, 914, 10.1001/jama.285.7.914 · DOI · Paper page
  5. Dwamena, 1999, Metastases from non-small cell lung cancer: mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT, Radiology, 213, 530, 10.1148/radiology.213.2.r99nv46530 · DOI · Paper page
  6. Toloza, 2003, Noninvasive staging of nonsmall cell lung cancer: a review of the current evidence, Chest, 123, S137, 10.1378/chest.123.1_suppl.137S · DOI · Paper page
  7. Pieterman, 2000, Preoperative staging of non-small cell lung cancer with positron emission tomography, N Engl J Med, 343, 254, 10.1056/NEJM200007273430404 · DOI · Paper page
  8. Duhaylongsod, 1995, Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography, Ann Thorac Surg, 60, 1348, 10.1016/0003-4975(95)00754-9 · DOI · Paper page
  9. Ahuja, 1998, The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma, Cancer, 83, 918, 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y · DOI · Paper page
  10. Vansteenkiste, 1999, Prognostic importance of the Standardized Uptake Value on FDG-PET-scan in non-small cell lung cancer: an analysis of 125 cases, J Clin Oncol, 17, 3201, 10.1200/JCO.1999.17.10.3201 · DOI · Paper page
  11. Dhital, 2000, [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer, Eur J Cardiothorac Surg, 18, 425, 10.1016/S1010-7940(00)00535-2 · DOI
  12. Higashi, 2002, 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer, J Nucl Med, 43, 39
  13. Jeong, 2002, Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer, Nucl Med Commun, 23, 865, 10.1097/00006231-200209000-00010 · DOI
  14. Dunagan, 2001, Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer, Chest, 119, 333, 10.1378/chest.119.2.333 · doi:10.1378/chest.119.2.333
  15. MacManus, 2001, F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma: powerful correlation with survival and high impact on treatment, Cancer, 92, 886, 10.1002/1097-0142(20010815)92:4<886::AID-CNCR1397>3.0.CO;2-V · doi:10.1002/1097-0142(20010815)92:4<886::aid-cncr1397>3.0.co;2-v
  16. MacManus, 2002, Early mortality after radical radiotherapy for non-small cell lung cancer: comparison of PETstaged and conventionally staged cohorts treated at a large tertiary referral center, Int J Radiat Oncol Biol Phys, 52, 351, 10.1016/S0360-3016(01)02673-6 · doi:10.1016/s0360-3016(01)02673-6
  17. Hoekstra, 2003, The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment, Lung Cancer, 39, 151, 10.1016/S0169-5002(02)00446-4 · doi:10.1016/s0169-5002(02)00446-4
  18. Feinstein, 1985, The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer, N Engl J Med, 312, 1604, 10.1056/NEJM198506203122504 · DOI · Paper page
  19. The International Adjuvant Lung Cancer Trial Collaborative Group, 2004, Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer, N Engl J Med, 350, 351, 10.1056/NEJMoa031644 · DOI · Paper page
  20. Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 · DOI · Paper page
  21. Higashi, 1993, Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake, J Nucl Med, 34, 414
  22. Ichiya, 1996, A clinical evaluation of FDGPET to assess the response in radiation therapy for bronchogenic carcinoma, Ann Nucl Med, 10, 193, 10.1007/BF03165392 · DOI
  23. Choi, 2002, Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 54, 1024, 10.1016/S0360-3016(02)03038-9 · DOI
  24. MacManus, 2003, Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer, J Clin Oncol, 21, 1285, 10.1200/JCO.2003.07.054 · DOI · Paper page
  25. Weber, 2003, Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use, J Clin Oncol, 21, 2651, 10.1200/JCO.2003.12.004 · DOI · Paper page
  26. Hoekstra, 2002, Methods to monitor response to chemotherapy in non-small cell lung cancer with 18FFDG PET, J Nucl Med, 43, 1304
  27. Young, 1999, Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations, Eur J Cancer, 35, 1773, 10.1016/S0959-8049(99)00229-4 · DOI · Paper page
  28. Bueno, 2001, Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival, Ann Thorac Surg, 70, 1826, 10.1016/S0003-4975(00)01585-X · DOI · Paper page
  29. Voltolini, 2001, Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy, Eur J Cardiothorac Surg, 20, 1106, 10.1016/S1010-7940(01)00984-8 · doi:10.1016/s1010-7940(01)00984-8
  30. Margaritora, 2001, Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging?, Eur J Cardiothorac Surg, 19, 894, 10.1016/S1010-7940(01)00697-2 · doi:10.1016/s1010-7940(01)00697-2
  31. Vansteenkiste, 1998, Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients, J Clin Oncol, 16, 2142, 10.1200/JCO.1998.16.6.2142 · DOI · Paper page
  32. Vansteenkiste, 1998, Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIA-N2 non-small cell lung cancer: a prospective pilot study, Ann Oncol, 9, 1193, 10.1023/A:1008437915860 · DOI
  33. Akhurst, 2002, An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer, Ann Thorac Surg, 73, 259, 10.1016/S0003-4975(01)03257-X · DOI
  34. Ryu, 2002, FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology, Lung Cancer, 35, 179, 10.1016/S0169-5002(01)00332-4 · DOI · Paper page
  35. Cerfolio, 2003, Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma, J Thorac Cardiovasc Surg, 125, 938, 10.1067/mtc.2003.381 · doi:10.1067/mtc.2003.381
  36. Vansteenkiste, 2001, 18fluoro-2- deoxyglucose positron emission tomography (PET) in the assessment of induction chemotherapy (IC) in stage IIIA-N2 NSCLC: a multicenter prospective study, Proc Am Soc Clin Oncol, 20, A313
  37. Vesselle, 2002, The impact of fluorodeoxyglucose F18 positron emission tomography on the surgical staging of non-small cell lung cancer, J Thorac Cardiovasc Surg, 124, 511, 10.1067/mtc.2002.123130 · DOI
  38. Patz, 2000, Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer, AJR Am J Roentgenol, 174, 769, 10.2214/ajr.174.3.1740769 · doi:10.2214/ajr.174.3.1740769
  39. Hicks, 2001, The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification, J Nucl Med, 42, 1605
  40. Pandit, 2003, Prognostic value of [(18)F]FDG-PET imaging in small cell lung cancer, Eur J Nucl Med Mol Imaging, 30, 78, 10.1007/s00259-002-0937-8 · doi:10.1007/s00259-002-0937-8
  41. Kubota, 1993, Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C]methionine: a preliminary study, Eur J Nucl Med, 20, 495, 10.1007/BF00175162 · DOI
  42. Patz, 1994, Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy- D-glucose, Radiology, 191, 379, 10.1148/radiology.191.2.8153309 · DOI
  43. Duhaylongsod, 1995, Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET), J Thorac Cardiovasc Surg, 110, 130, 10.1016/S0022-5223(05)80018-2 · DOI · Paper page
  44. Frank, 1995, Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings, Int J Radiat Oncol Biol Phys, 32, 1495, 10.1016/0360-3016(94)00622-R · DOI
  45. Inoue, 1995, Detecting recurrent or residual lung cancer with FDG-PET, J Nucl Med, 36, 788
  46. Bury, 1999, Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer, Eur Respir J, 14, 1376, 10.1183/09031936.99.14613769 · DOI
  47. Ukena, 2000, Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in diagnosis of recurrent bronchial carcinoma, Pneumologie, 54, 49, 10.1055/s-2000-9063 · doi:10.1055/s-2000-9063
  48. Lee, 2001, Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review, Chest, 120, 1791, 10.1378/chest.120.6.1791 · doi:10.1378/chest.120.6.1791

Cited by

See all 231

Metadata

Authors
Vansteenkiste, J., Fischer, B. M., Dooms, C., & Mortensen, J.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2004-09
Volume
5
Issue
9
Pages
531-540
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2143000781
Cited by
231
References
1
FWCI
2.88
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. https://app.cochat.ai/papers/10.1016/s1470-2045(04)01564-5
The paper
Vansteenkiste, J., Fischer, B. M., Dooms, C., & Mortensen, J. (2004). Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(04)01564-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.